Trial Profile
Phase I Dose Escalation Study of Intraperitoneal (I.P.) ONTAK Administered to Patients With Advanced Stage Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 13 May 2019 Status changed from active, no longer recruiting to completed.
- 13 May 2019 Status changed from active, no longer recruiting to completed.
- 13 Sep 2010 Planned end date changed from 1 Jun 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.